These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36282537)

  • 1. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study.
    Östör A; Van den Bosch F; Papp K; Asnal C; Blanco R; Aelion J; Lu W; Wang Z; Soliman AM; Eldred A; Padilla B; Kivitz A
    Rheumatology (Oxford); 2023 Jun; 62(6):2122-2129. PubMed ID: 36282537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study.
    Kristensen LE; Keiserman M; Papp K; McCasland L; White D; Lu W; Soliman AM; Eldred A; Barcomb L; Behrens F
    Rheumatology (Oxford); 2023 Jun; 62(6):2113-2121. PubMed ID: 36282530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial.
    Östör A; Van den Bosch F; Papp K; Asnal C; Blanco R; Aelion J; Carter K; Stakias V; Lippe R; Drogaris L; Soliman AM; Chen MM; Padilla B; Kivitz A
    Rheumatol Ther; 2024 Jun; 11(3):633-648. PubMed ID: 38498139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial.
    Kristensen LE; Keiserman M; Papp K; McCasland L; White D; Carter K; Lippe R; Photowala H; Drogaris L; Soliman AM; Chen M; Padilla B; Behrens F
    Rheumatol Ther; 2024 Jun; 11(3):617-632. PubMed ID: 38498141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial.
    Östör A; Van den Bosch F; Papp K; Asnal C; Blanco R; Aelion J; Alperovich G; Lu W; Wang Z; Soliman AM; Eldred A; Barcomb L; Kivitz A
    Ann Rheum Dis; 2022 Mar; 81(3):351-358. PubMed ID: 34815219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial.
    Kristensen LE; Keiserman M; Papp K; McCasland L; White D; Lu W; Wang Z; Soliman AM; Eldred A; Barcomb L; Behrens F
    Ann Rheum Dis; 2022 Feb; 81(2):225-231. PubMed ID: 34911706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials.
    Merola JF; Armstrong A; Khattri S; Paek SY; Padilla B; Yue C; Photowala H; Kaplan B; Kristensen LE
    J Dermatolog Treat; 2024 Dec; 35(1):2342383. PubMed ID: 38632977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1.
    Kristensen LE; Soliman AM; Papp K; White D; Barcomb L; Lu W; Eldred A; Behrens F
    Rheumatology (Oxford); 2023 Feb; 62(2):629-637. PubMed ID: 35801915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2.
    Ostor AJK; Soliman AM; Papp KA; Padilla B; Wang Z; Eldred A; de Vlam K; Kivitz A
    RMD Open; 2022 Jun; 8(2):. PubMed ID: 35701011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
    Deodhar A; Helliwell PS; Boehncke WH; Kollmeier AP; Hsia EC; Subramanian RA; Xu XL; Sheng S; Agarwal P; Zhou B; Zhuang Y; Ritchlin CT;
    Lancet; 2020 Apr; 395(10230):1115-1125. PubMed ID: 32178765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
    Blauvelt A; Leonardi CL; Gooderham M; Papp KA; Philipp S; Wu JJ; Igarashi A; Flack M; Geng Z; Wu T; Camez A; Williams D; Langley RG
    JAMA Dermatol; 2020 Jun; 156(6):649-658. PubMed ID: 32267471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.
    Ritchlin CT; Coates LC; McInnes IB; Mease PJ; Merola JF; Tanaka Y; Asahina A; Gossec L; Gottlieb AB; Warren RB; Ink B; Bajracharya R; Shende V; Coarse J; Landewé RB
    Ann Rheum Dis; 2023 Nov; 82(11):1404-1414. PubMed ID: 37696588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of risankizumab on achieving minimal clinically important differences in patient-reported outcomes in patients with psoriatic arthritis: results from KEEPsAKE 1 and 2.
    Kristensen LE; Soliman AM; Papp K; Barcomb L; Eldred A; Östör A
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2120-2129. PubMed ID: 35920763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
    Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial.
    Mease PJ; Kellner H; Morita A; Kivitz AJ; Aslanyan S; Padula SJ; Topp AS; Eldred A; Behrens F; Papp KA
    Rheumatol Ther; 2022 Oct; 9(5):1361-1375. PubMed ID: 35931879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enthesitis and Dactylitis Resolution with Risankizumab for Active Psoriatic Arthritis: Integrated Analysis of the Randomized KEEPsAKE 1 and 2 Trials.
    Kwatra SG; Khattri S; Amin AZ; Ranza R; Kaplan B; Shi L; Padilla B; Soliman AM; McGonagle D
    Dermatol Ther (Heidelb); 2024 Jun; 14(6):1517-1530. PubMed ID: 38739215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
    Genovese MC; Mease PJ; Thomson GT; Kivitz AJ; Perdok RJ; Weinberg MA; Medich J; Sasso EH;
    J Rheumatol; 2007 May; 34(5):1040-50. PubMed ID: 17444593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.
    Mease PJ; Lertratanakul A; Anderson JK; Papp K; Van den Bosch F; Tsuji S; Dokoupilova E; Keiserman M; Wang X; Zhong S; McCaskill RM; Zueger P; Pangan AL; Tillett W
    Ann Rheum Dis; 2021 Mar; 80(3):312-320. PubMed ID: 33272960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
    Mease PJ; Rahman P; Gottlieb AB; Kollmeier AP; Hsia EC; Xu XL; Sheng S; Agarwal P; Zhou B; Zhuang Y; van der Heijde D; McInnes IB;
    Lancet; 2020 Apr; 395(10230):1126-1136. PubMed ID: 32178766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.
    McInnes IB; Rahman P; Gottlieb AB; Hsia EC; Kollmeier AP; Xu XL; Jiang Y; Sheng S; Shawi M; Chakravarty SD; van der Heijde D; Mease PJ
    Arthritis Rheumatol; 2022 Mar; 74(3):475-485. PubMed ID: 34719872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.